The purpose of this study is to examine the extent of mpox viral spread and immunologic markers in people with advanced HIV. Study findings will enhance knowledge of mpox pathogenesis in severely immunocompromised people, which can inform treatment and prevention of severe illness and deaths associated with mpox in people with advanced HIV.
Primary objective: Describe the relationship between the systemic immunologic response and the persistence and replication competence of mpox virus at rash lesions, in blood, and at mucosal sites over the course of mpox illness among patients with advanced HIV. Secondary objectives: * Describe the association between clinical outcomes and virologic and immunologic parameters among patients with severe mpox and advanced HIV. * Survey for emergence of antiviral drug resistance among MPXV isolates collected over time during mpox illness among patients with advanced HIV. * Characterize the effects of antivirals to treat mpox and/or HIV infection on virologic and immunologic parameters among patients with mpox and advanced HIV. * Assess persistence and replication competence of mpox virus in the oropharynx and rectum over the course of mpox illness among patients with advanced HIV.
Study Type
OBSERVATIONAL
Enrollment
100
Centers for Disease Control and Prevention
Atlanta, Georgia, United States
RECRUITINGMonkeypox viral persistence
Monkeypox virus persistence in different sample types (including lesion, oropharyngeal, and rectal swabs; blood) over the course of illness
Time frame: While hospitalized, for up to 12 months
Monkeypox viral viability
Monkeypox virus viability in different sample types (including lesion, oropharyngeal, and rectal swabs; blood) over the course of illness
Time frame: While hospitalized, for up to 12 months
Immune response
Cytokine and chemokine profile over the course of illness
Time frame: While hospitalized, for up to 12 months
Clinical outcome
Duration of illness from mpox
Time frame: Up to 12 months
Clinical outcome
Duration of hospitalization with mpox
Time frame: Up to 12 months
Clinical outcome
Duration of critical illness due to mpox
Time frame: Up to 12 months
Clinical outcome
Mpox lesion burden
Time frame: Up to 12 months
Clinical outcome
Mortality
Time frame: Up to 12 months
Clinical outcome
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Characterization of co-infections
Time frame: Up to 12 months
Monkeypox virus resistance
Assess Monkeypox virus isolates for resistance to available therapeutics over the course of illness
Time frame: While hospitalized, for up to 12 months